Cresset Asset Management’s HCW Biologics HCWB Stock Holding History

Cresset Asset Management’s Portfolio HCWB Stock Details HCWB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-550	Closed	-$37.2K	–	1593
2025 Q1	$37.2K	Hold	550	–	–	﹤0.01%	1668
2024 Q4	$58.9K	Hold	550	–	–	﹤0.01%	1655
2024 Q3	$71.2K	Hold	550	–	–	﹤0.01%	2066
2024 Q2	$85.4K	Hold	550	–	–	﹤0.01%	1970
2024 Q1	$231K	Hold	550	–	–	﹤0.01%	1703
2023 Q4	$162K	Hold	550	–	–	﹤0.01%	1720
2023 Q3	$251K	Hold	550	–	–	﹤0.01%	1518
2023 Q2	$286K	Buy	550 +477	+653%	+$190K	﹤0.01%	1549
2023 Q1	$24.6K	Hold	73	–	–	﹤0.01%	803
2022 Q4	$33.6K	Hold	73	–	–	﹤0.01%	692
2022 Q3	$40K	Hold	73	–	–	﹤0.01%	861
2022 Q2	$39K	Hold	73	–	–	﹤0.01%	917
2022 Q1	$48K	Buy	73 +21	+40%	+$11.2K	﹤0.01%	973
2021 Q4	$29K	Buy	+52	New	+$35.3K	﹤0.01%	1115

Other funds holding HCWB

GSWM

Golden State Wealth Management Santa Ana, California $1.1B AUM 27.5% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

FFO

Fortitude Family Office Scottsdale, Arizona $516M AUM 28.38% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Cresset Asset Management's HCWB Position: Q2 2025 in Review

Cresset Asset Management sold out of HCW Biologics (HCWB) in Q2 2025, closing a stake of 550 shares — an estimated $37.2K sold.

Cresset Asset Management first reported a position in HCWB in Q4 2021 and held it in 14 quarters. The position peaked at $286K in Q2 2023. 8 funds tracked by Wall St. Rank hold HCWB as of Q2 2025.

Cresset Asset Management reported no remaining HCW Biologics position as of Q2 2025 after selling out during the quarter.
Cresset Asset Management sold 550 HCW Biologics shares in Q2 2025, an estimated $37.2K.
Cresset Asset Management first reported a position in HCW Biologics in Q4 2021 and held it in 14 quarters.
Cresset Asset Management's HCW Biologics position peaked at $286K in Q2 2023.
8 funds tracked by Wall St. Rank held HCW Biologics as of Q2 2025.

Based on Cresset Asset Management's 13F filing for Q2 2025, filed 13 Aug 2025.